{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:35:02Z","timestamp":1791221702313,"version":"4.1.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.beha.2025.101615","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T09:14:53Z","timestamp":1744622093000},"page":"101615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Endogenous and exogenous cytokines: An overview and introduction"],"prefix":"10.1016","volume":"38","author":[{"given":"Thomas R.","family":"Spitzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.beha.2025.101615_bib1","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1002\/eji.200737772","article-title":"Historical review of cytokines","volume":"37","author":"Dinarello","year":"2007","journal-title":"Eur J Immunol"},{"issue":"12","key":"10.1016\/j.beha.2025.101615_bib2","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028472","article-title":"Cytokines in cancer immunotherapy","volume":"10","author":"Waldmann","year":"2018","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"10.1016\/j.beha.2025.101615_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br J Cancer"},{"issue":"23","key":"10.1016\/j.beha.2025.101615_bib4","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.3390\/ijms20236008","article-title":"Cytokines in inflammatory disease","volume":"20","author":"Kany","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.beha.2025.101615_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/acg2.98","article-title":"Cytokine syndromes associated with hematopoietic cellular therapy","author":"Spitzer","year":"2021","journal-title":"Adv Cell Gene Ther"},{"key":"10.1016\/j.beha.2025.101615_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4062\/biomolther.2023.196","article-title":"Current development status of cytokines for cancer immunotherapy","volume":"32","author":"Song","year":"2024","journal-title":"Biomol Ther"},{"key":"10.1016\/j.beha.2025.101615_bib7","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41584-019-0277-8","article-title":"The IL-1 family of cytokines and receptors in rheumatic diseases","volume":"15","author":"Dinarello","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.beha.2025.101615_bib8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1016\/j.beha.2025.101615_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome","volume":"8","author":"Murthy","year":"2019","journal-title":"ImmunoTargets Ther"},{"key":"10.1016\/j.beha.2025.101615_bib10","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1182\/blood-2003-08-2864","article-title":"Donor treatment with pegylated G-CSF augments the generation of IL-10-produciing regulatory T cells and promotes transplantation tolerance","volume":"103","author":"Morris","year":"2004","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101615_bib11","first-page":"161","article-title":"IL-10 signaling in T cells is essential for induction of transplant tolerance","volume":"204","author":"Lozano","year":"2020","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.beha.2025.101615_bib12","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3390\/cells10051248","article-title":"IL-10 mediated immunomodulation limits subepithelial fibrosis and repairs airway epithelium in rejecting airway allografts","volume":"10","author":"Khan","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.beha.2025.101615_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1172\/JCI1368","article-title":"IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses","volume":"101","author":"Xing","year":"1998","journal-title":"J Clin Investig"},{"key":"10.1016\/j.beha.2025.101615_bib14","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.15252\/embj.201488856","article-title":"The good, the bad, and the ugly of interleukin-6 signaling","volume":"33","author":"Fuster","year":"2014","journal-title":"EMBO J"},{"key":"10.1016\/j.beha.2025.101615_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nri705","article-title":"Th1 and Th2 cells: a historical perspective","volume":"2","author":"Liew","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib16","doi-asserted-by":"crossref","unstructured":"Ruterbusch M, Pruner KB, Shehata L, Pepper M. In vivo CD4+ T cell differentiation and function: revisiting the Th1\/Th2 paradigm. Annu Rev Immunol 202; 38:705-725.","DOI":"10.1146\/annurev-immunol-103019-085803"},{"key":"10.1016\/j.beha.2025.101615_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nm1551","article-title":"A brief history of Th17, the first major revision in the Th1\/Th2 hypothesis of T cell-mediated tissue damage","volume":"13","author":"Steinman","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2025.101615_bib18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1600-0897.2010.00852.x","article-title":"Th1\/Th2\/Th17 and regulatory T-cell paradigm in pregnancy","volume":"63","author":"Saito","year":"2010","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.12703\/r\/10-30","article-title":"Recent advances in understanding the Th1\/Th2 effector choice","volume":"10","author":"Butcher","year":"2021","journal-title":"Fac Rev"},{"key":"10.1016\/j.beha.2025.101615_bib20","doi-asserted-by":"crossref","unstructured":"Wu X, Tian J and Wang S. Insight into non-pathogenic Th17 cells in autoimmune diseases. Front Immunol 9:1112.doi: 10.3389\/fimmu.2018.01112.","DOI":"10.3389\/fimmu.2018.01112"},{"key":"10.1016\/j.beha.2025.101615_bib21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101615_bib22","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40744-021-00418-5","article-title":"Effectiveness of etanercept in rheumatoid arthritis: real-world data from the German Non-interventional Study ADEQUATE with focus on treat-to-target and patient-reported outcomes","volume":"9","author":"Feist","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.beha.2025.101615_bib23","doi-asserted-by":"crossref","unstructured":"Agrawal V, Griffin SP, Koch L, Thakrar TC, Ervin KD, Schmidt CA, et al. Outcomes of infliximab in management of steroid-refractory acute graft versus host disease. Transplant Cell Ther. DOI:https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.250.","DOI":"10.1016\/j.bbmt.2018.12.250"},{"key":"10.1016\/j.beha.2025.101615_bib24","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/blood.V80.12.2964.2964","article-title":"Cytokine dysregulation and acute graft versus host disease","volume":"80","author":"Antin","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101615_bib25","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.4049\/jimmunol.1500117","article-title":"Cytokines in graft-versus-host disease","volume":"194","author":"Henden","year":"2015","journal-title":"J Immunol"},{"issue":"2452","key":"10.1016\/j.beha.2025.101615_bib26","first-page":"2463","article-title":"Cytokine mediators of chronic graft-versus-host disease","volume":"127","author":"MacDonald","year":"2017","journal-title":"J Clin Investig"},{"key":"10.1016\/j.beha.2025.101615_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cyto.2014.09.011","article-title":"T cell subsets and their signature cytokines in autoimmune and inflammatory diseases","volume":"74","author":"Raphael","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.beha.2025.101615_bib28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1182\/blood.2019001333","article-title":"Hermiston. Calming the storm in HLH","volume":"134","author":"Zinter","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101615_bib29","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.bbmt.2015.12.016","article-title":"Cytokine profile of engraftment syndromes in pediatric hematopoietic stem cell transplant recipients","volume":"22","author":"Khandelwal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101615_bib30","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101615_bib31","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.bbmt.2014.08.014","article-title":"Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease","volume":"21","author":"Al-Homsi","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101615_bib32","first-page":"2437","article-title":"Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation","volume":"2431","author":"Imus","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101615_bib33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cll.2008.08.001","article-title":"Yin and yang of cytokine regulation in solid organ graft rejection and tolerance","volume":"28","author":"Wadia","year":"2008","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.beha.2025.101615_bib34","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1097\/TP.0000000000004572","article-title":"An Immune atlas of T Cells in transplant rejection: pathways and therapeutic opportunities","volume":"107","author":"Short","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.beha.2025.101615_bib35","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1056\/NEJMe2204651","article-title":"Transplantation tolerance through hematopoietic chimerism","volume":"386","author":"Spitzer","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101615_bib36","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1084\/jem.147.3.700","article-title":"Transplantation tolerance in adult rats using total lymphoid irradiation: permanent survival of skin, heart, and marrow allografts","volume":"147","author":"Slavin","year":"1978","journal-title":"J Exp Med"},{"key":"10.1016\/j.beha.2025.101615_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0167-5699(88)91352-7","article-title":"Mixed allogeneic chimerism as an approach to transplantation tolerance","volume":"9","author":"Sykes","year":"1988","journal-title":"Immunol Today"},{"key":"10.1016\/j.beha.2025.101615_bib38","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1097\/TP.0000000000002669","article-title":"Twenty year follow up of histocompatibility leukocyte antigen-matched kidney and bone marrow Co-transplantation for multiple myeloma with end stage renal disease: lessons learned","volume":"103","author":"Spitzer","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.beha.2025.101615_bib39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1056\/NEJMoa071074","article-title":"HLA mismatched renal transplantation without maintenance immunosuppression","volume":"358","author":"Kawai","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101615_bib40","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.7010.1","article-title":"Regulation of IL-10 and IL-12 production and function in macrophage and dendritic cells","volume":"4","author":"Ma","year":"2015","journal-title":"F1000Res"},{"key":"10.1016\/j.beha.2025.101615_bib41","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.7634.1","article-title":"IL-21 Signaling in Immunity","volume":"5","author":"Leonard","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.beha.2025.101615_bib42","first-page":"599","volume":"vol. 116","author":"Santana","year":"2018"},{"key":"10.1016\/j.beha.2025.101615_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.747324","article-title":"Interleukin-7 biology and its effect on immune cells: mediator of generation, differentiation, survival and homeostasis","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib44","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.beha.2025.101615_bib45","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.4049\/jimmunol.0903210","article-title":"IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms","volume":"184","author":"Sorensen","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib46","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/ibd.22929","article-title":"Healing of intestinal inflammation by IL-22","volume":"18","author":"Mizoguchi","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.beha.2025.101615_bib47","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1146\/annurev-immunol-032414-112123","article-title":"Interleukin-22: immunology and pathology","volume":"33","author":"Dudakov","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib48","doi-asserted-by":"crossref","first-page":"214","DOI":"10.5114\/ceji.2020.97911","article-title":"Interleukin 39: a new member of interleukin 12 family","volume":"45","author":"Lu","year":"2020","journal-title":"Cent Eur J Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib49","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib50","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/JLB.2RI0717-278R","article-title":"Biology of IL-2 and its therapeutic modulation: mechanisms and strategies","volume":"103","author":"Mitra","year":"2018","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.beha.2025.101615_bib51","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101615_bib52","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1182\/bloodadvances.2023009729","article-title":"Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease","volume":"22","author":"Wobma","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2025.101615_bib53","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-Infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101615_bib54","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_431608","article-title":"Adoptive cell therapy for solid tumors: current status in melanoma and next-generation therapies","volume":"44","author":"Haanen","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.beha.2025.101615_bib55","unstructured":"Mortezaee K, Majidpoor. Checkpoint inhibitor\/interleukin-based combination therapy of cancer. Cancer Med. DOI: 10.1002\/cam4.4659.T."},{"key":"10.1016\/j.beha.2025.101615_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104539","article-title":"A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases","volume":"90","author":"Raeber","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.beha.2025.101615_bib57","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2159-8290.CD-19-1510","article-title":"Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02)","volume":"10","author":"Diab","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.beha.2025.101615_bib58","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1158\/1078-0432.CCR-20-1319","article-title":"IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy","volume":"27","author":"Teijeira","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2025.101615_bib59","first-page":"3184","article-title":"TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice","volume":"141","author":"Xie","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101615_bib60","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nri888","article-title":"Viruses and interferon: a fight for supremacy","volume":"2","author":"Katze","year":"2002","journal-title":"Nature Rev Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib61","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0168-8278(03)00207-1","article-title":"Mechanisms of action of interferon and nucleoside analogues","volume":"39","author":"Thomas","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.beha.2025.101615_bib62","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I and type-II interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nature Rev Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib63","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022112907","article-title":"Viral recognition and the antiviral initerferon response","author":"Dalskov","year":"2023","journal-title":"EMBO J"},{"key":"10.1016\/j.beha.2025.101615_bib64","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1182\/blood.V58.4.712.712","article-title":"Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin\u2019s lymphoma","volume":"58","author":"Louie","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101615_bib65","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0898-6568(98)00018-7","article-title":"TNF-related ligands and their receptors","author":"Orlinick","year":"1998","journal-title":"Cell Signal"},{"key":"10.1016\/j.beha.2025.101615_bib66","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF00253968","article-title":"Phase I clinical trial of recombinant human tumor necrosis factor","volume":"20","author":"Creaven","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.beha.2025.101615_bib67","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxu102","article-title":"anti-TNF therapy: past, present and future","volume":"27","author":"Monaco","year":"2015","journal-title":"Int Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib68","doi-asserted-by":"crossref","unstructured":"Orfanoudaki E, Foteinogiannopoulou K, Theodoraki E, Koutroubakis IE. Recent Advances in the optimization of anti-TNF treatment in patients with Inflammatory bowel disease. J Clin Med 12(7), 2452; https:\/\/doi.org\/10.3390\/jcm120724522023.","DOI":"10.3390\/jcm12072452"},{"key":"10.1016\/j.beha.2025.101615_bib69","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMra052723","article-title":"The many roles of chemokines and chemokine receptors in inflammation","volume":"354","author":"Charo","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101615_bib70","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nri3049","article-title":"Homeostatic chemokine receptors and organ-specific metatstasis","volume":"11","author":"Zlotnik","year":"2011","journal-title":"Nature Rev Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib71","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.immuni.2012.05.008","article-title":"The chemokine superfmily revisited","volume":"36","author":"Zlotnik","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.beha.2025.101615_bib72","first-page":"403","article-title":"Use of plerixafor for stem cell mobilization in the setting of autologous and allogeneic stem cell transplantation: an update","volume":"12","author":"Bilgin","year":"2021","journal-title":"Hematol Res Rev"},{"key":"10.1016\/j.beha.2025.101615_bib73","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101615_bib74","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231174304","article-title":"Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide","volume":"14","author":"Crees","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.beha.2025.101615_bib75","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1182\/blood-2014-12-618090","article-title":"TGF-beta signaling in the control of hematopoietic stem cells","volume":"125","author":"Blank","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101615_bib76","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","article-title":"TGF-beta signaling in health, disease and therapeutics","volume":"9","author":"Deng","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.beha.2025.101615_bib77","first-page":"9","article-title":"TGF\u03b2 biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nar Rev Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib78","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0167-5699(84)90170-1","article-title":"Hematopoietic colony-stimulating factors","volume":"5","author":"Nicola","year":"1984","journal-title":"Immunol Today"},{"issue":"7","key":"10.1016\/j.beha.2025.101615_bib79","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nri2356","article-title":"Colony-stimulating factors in inflammation and autoimmunity","volume":"8","author":"Hamilton","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib80","first-page":"129","article-title":"Erythropoietin: a review","volume":"86","author":"Ridley","year":"1994","journal-title":"J Natl Med Assoc"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2025.101615_bib81","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12959-016-0095-z","article-title":"Thrombopoietin and its receptor in normal and neoplastic hematopoiesis","volume":"14","author":"Kaushansky","year":"2016","journal-title":"Thromb J"},{"key":"10.1016\/j.beha.2025.101615_bib82","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1016\/j.jtct.2023.12.261","article-title":"Efficacy of siltuximab for chimeric antigen receptor T-cell therapy toxicities-a multicenter retrospective analysis","volume":"30","author":"Bajwa","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.beha.2025.101615_bib83","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.coph.2018.05.010","article-title":"Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases","volume":"41","author":"Hafeez","year":"2018","journal-title":"Curr Opinion Phrmacol"},{"key":"10.1016\/j.beha.2025.101615_bib84","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1574884712666170809124728","article-title":"Monoclonal antibodies: a review","volume":"13","author":"Singh","year":"2018","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.beha.2025.101615_bib85","author":"Kothari","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.beha.2025.101615_bib86","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s13555-021-00677-8","article-title":"Role of Interleukin 36 in generalized pustular psoriasis and beyond","volume":"12","author":"Sugiura","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.beha.2025.101615_bib87","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.2019002289","article-title":"Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis","volume":"134","author":"Vallurupalli","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101615_bib88","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pharmthera.2016.10.016","article-title":"Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation","volume":"169","author":"Nixon","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.beha.2025.101615_bib89","article-title":"Monoclonal antibodies in the management of asthma: dead ends, current status and future perspectives","volume":"13","author":"Karda","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib90","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2025.101615_bib91","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/eji.202048922","article-title":"JAK inhibitors: ten years after","volume":"51","author":"Spinelli","year":"2021","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib92","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.beha.2025.101615_bib93","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH 1): a multicenter, open-label, phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101615_bib94","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101615_bib95","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.beha.2025.101615_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1185716","article-title":"Tocilizumab versus anakinra in COVID-19: results from propensity score matching","volume":"14","author":"Arcani","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib97","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.bbmt.2014.02.026","volume":"20","author":"Yanik","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101615_bib98","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.6004\/jnccn.2017.0175","article-title":"Myeloid growth factors, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Crawford","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.beha.2025.101615_bib99","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1667\/RR15363.1","article-title":"Use of growth factors and other cytokines for treatment of injuries during a radiation public health emergency","volume":"192","author":"DiCarlo","year":"2019","journal-title":"Radiat Res"},{"key":"10.1016\/j.beha.2025.101615_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.706186","article-title":"Sargramostim (rhu GM-CSF) as cancer therapy (systematic review) and an immunomodulator. A drug before its time?","volume":"12","author":"Lazarus","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2025.101615_bib101","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/14712598.2022.2143261","article-title":"Sargramostim in acute radiation syndrome","volume":"22","author":"Lazarus","year":"2022","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.beha.2025.101615_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1069444","article-title":"Recombinant GM-CSF for diseases of GM-CSF insufficiency: correcting dysfunctional mononuclear phagocyte disorders","volume":"13","author":"Lazarus","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.beha.2025.101615_bib103","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/cancers16030501","article-title":"Sargramostim for prophylactic management of gastrointestinal immune-related adverse events of immune checkpoint inhibitor therapy for cancer","volume":"16","author":"Dougan","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.beha.2025.101615_bib104","first-page":"1","article-title":"G-CSF and GM-CSF are different. Which one is better for COVID-19?","volume":"13","author":"Lazarus","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.beha.2025.101615_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2018.07.032","article-title":"G-CSF mediates lung injury in mice with adenine-induced acute kidney injury","volume":"63","author":"Jing","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.beha.2025.101615_bib106","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa1816216","article-title":"Inhaled GM-CSF for pulmonary alveolar proteinosis","volume":"381","author":"Tazawa","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101615_bib107","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.bbmt.2009.03.015","article-title":"Clinical and ultrasonic evaluation of spleen size during peripheral blood progenitor cell mobilization by filgrastim: results of an open-label trial in normal donors","volume":"15","author":"Stiff","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101615_bib108","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.bbmt.2011.07.003","article-title":"Can G-CSF cause leukemia in hematopoietic stem cell donors?","volume":"17","author":"Avalos","year":"2011","journal-title":"Biol Bone Marrow Transp"},{"key":"10.1016\/j.beha.2025.101615_bib109","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/s41409-022-01617-6","article-title":"Cancer incidence in healthy Swedish peripheral blood stem cell donors","volume":"57","author":"Pahnke","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101615_bib110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/CJI.0000000000000149","article-title":"Clinical Response Rates from interleukin-2 therapy for metastatic melanoma over 30 years' experience: a meta-analysis of 3312 Patients","volume":"40","author":"Bright","year":"2017","journal-title":"J Immunother"},{"issue":"39","key":"10.1016\/j.beha.2025.101615_bib111","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-Infiltrating lymphocyte therapy, in metastatic melanoma","volume":"20","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2025.101615_bib112","doi-asserted-by":"crossref","unstructured":"McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF. et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol https:\/\/doi.org\/10.1200\/JCO.2005.03.206.","DOI":"10.1200\/JCO.2005.03.206"},{"key":"10.1016\/j.beha.2025.101615_bib113","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2217\/imt-2019-0217","article-title":"Interferons: role in cancer therapy","volume":"12","author":"Abdolvahab","year":"2020","journal-title":"Immunotherapy"},{"issue":"12","key":"10.1016\/j.beha.2025.101615_bib114","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3390\/cancers11121943","article-title":"Type I interferons and cancer: an evolving story demanding novel clinical applications","volume":"11","author":"Aric\u00f2","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.beha.2025.101615_bib115","article-title":"Anemia in chronic kidney disease: from pathophysiology and current treatments to future agents","volume":"8","author":"Portoles","year":"2021","journal-title":"Front. Med. 2021 Sec. Nephrology"},{"key":"10.1016\/j.beha.2025.101615_bib116","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.18.02142","article-title":"Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update","volume":"37","author":"Bohlius","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T07:04:38Z","timestamp":1753081478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692625000209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":116,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1521692625000209"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2025.101615","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endogenous and exogenous cytokines: An overview and introduction","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2025.101615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101615"}}